The Food and Drug Administration (FDA) has approved new dosage strength for Zubsolv (buprenorphine/naloxone sublingual tablet; Orexo) for the treatment of patients with opioid dependence.

The new 0.7mg/0.18mg sublingual tablet will provide clinicians with the lowest available single dose of buprenorphine/naloxone and allows for more dosing flexibility. Originally approved in July 2013, Zubsolv is now available in six different tablet strengths: 11.4mg/2.9mg, 8.6mg/2.1mg, 5.7mg/1.4mg, 2.9mg/0.71mg, 1.4mg/0.36mg, and 0.7mg/0.18mg.

Related Articles

Zubsolv, a CIII agent, is a partial opioid antagonist indicated for the treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine is a partial agonist at the mu-opioid receptors and and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors.

The new strength is expected to be available in early 2017.

For more information visit